In the RAS and BRAF wildtype cohort, the treatment arms were well balanced, apart from the primary tumour location in the PICCOLO trial, in which case the proportion of right-sided tumours was higher in the control (irinotecan) arm (Supplementary Table 2). Here, BRAF is linked to neoplasm.